Key Highlights

  • Clarity Pharmaceuticals (ASX: CU6) shares traded at AUD 2.86, rising 13.49% or AUD 0.34 on 5 August 2026.
  • The company reported updated SECuRE trial data for its 8 GBq 67Cu-SAR-bisPSMA treatment program.
  • Seven participants across the 67Cu-SAR-bisPSMA program have achieved complete response or undetectable disease outcomes.
  • Clinical results continue to support the company’s focus on targeted copper theranostic treatments for cancer.

Clarity Pharmaceuticals Ltd (ASX: CU6) recorded a share price of AUD 2.86, increasing by 13.49% or AUD 0.34 during trading on 5 August 2026 at 10:48 am. The movement followed the company’s latest clinical update from its SECuRE trial, which evaluated the 8 GBq dose level of 67Cu-SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer. The announcement highlighted additional complete responses and further clinical observations from the ongoing study.

Company Profile and Healthcare Focus

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company developing targeted copper theranostic products for cancer treatment. The company’s technology platform is designed to combine diagnostic imaging and therapeutic applications through the use of copper isotopes.

Its lead program, SAR-bisPSMA, focuses on prostate-specific membrane antigen (PSMA)-expressing cancers. The approach uses copper-64 for imaging and copper-67 for therapy, aiming to identify cancer lesions and deliver targeted treatment through a single molecular platform.

SECuRE Trial Update and Clinical Findings

The latest update relates to the SECuRE trial (NCT04868604), a Phase I/IIa study evaluating 64Cu/67Cu-SAR-bisPSMA for identifying and treating patients with PSMA-expressing metastatic castration-resistant prostate cancer.

The preliminary assessment included 19 participants who received the 8 GBq dose level, comprising three participants from the Dose Escalation phase and 16 participants from the ongoing Cohort Expansion phase. The data cut-off for the assessment was 20 July 2026.

Clinical observations showed reductions in prostate-specific antigen (PSA) levels among participants. According to the company, 74% of evaluable participants achieved PSA25 responses, while 63% achieved PSA50 responses. A total of 53% recorded PSA75 responses and 26% reached PSA90 responses.

Radiographic assessments showed that 81% of evaluable participants achieved disease control. This included stable disease outcomes and complete response or undetectable disease observations assessed through imaging and other clinical measures.

Complete Responses and Safety Observations

The company reported two additional participants achieving complete responses during the Cohort Expansion phase. These additions bring the total number of participants achieving complete response or undetectable disease across the 67Cu-SAR-bisPSMA program to seven.

Five of these seven participants received treatment at the 8 GBq dose level. The company noted that these outcomes were observed among patients who had previously undergone multiple cancer treatment regimens, including participants with advanced disease characteristics.

The safety profile from the 8 GBq dose assessment showed that most treatment-related adverse events were mild or moderate and temporary. Reported events included gastrointestinal and haematological effects, with no Grade 4 or higher related events reported in the assessed group.

Market Significance of Clarity’s Clinical Progress

For biotechnology companies, clinical trial milestones can influence market attention as investors assess the progress of experimental treatments toward potential future applications. Clarity’s latest update provides additional clinical data on SAR-bisPSMA and its application in prostate cancer treatment.

The company remains in the clinical development stage, and regulatory assessments will be required before any product can become commercially available. The safety and efficacy of 67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA have not yet been assessed by regulatory authorities such as the US Food and Drug Administration or the Therapeutic Goods Administration.

Conclusion

Clarity Pharmaceuticals continues to develop its radiopharmaceutical platform through ongoing clinical studies focused on cancer treatment. The latest SECuRE trial update provides additional information on patient responses, safety observations, and the potential role of 67Cu-SAR-bisPSMA in prostate cancer therapy. Future clinical data, regulatory progress, and further trial outcomes will remain key factors shaping market interest in ASX: CU6.